SIF guide
From SIF research to a decision brief
A practical handoff from public research to accountable questions, personalized fit review, final source checks, and a documented continue, pause, or close decision.
Key takeaway
A research platform should not turn a shortlist into a recommendation. Its final output should be a dated decision brief that preserves verified facts, assigns unresolved questions, records personal-fit and commercial disclosures, and makes pause or rejection as usable as proceeding.
The research handoff
Turn a researched SIF into a decision brief
Continue the fictional Meridian review from the due-diligence guide. This page shows how to preserve the evidence, ask accountable questions, and decide whether the case may move forward, must pause, or should close.
Fictional handoff case
Meridian Hybrid Long-Short Strategy
Illustrative name and evidence only. It is not a real SIF, personal advice, or a transaction instruction.
- Due-diligence result
- 4 pass / 3 pause
- Current workflow state
- Research complete; action not cleared
- Controlling issue
- Material evidence and personal fit still need accountable review
Decision brief
Four boxes keep the handoff honest
Verified facts
Exact strategy identity, final ISID, mandate, Rs. 10 lakh threshold, derivative permissions, and a dated Risk-band are supported.
Research interpretation
The hybrid long-short design may add a differentiated growth sleeve, but its portfolio role still depends on the investor's existing holdings and risk capacity.
Open evidence
The current notice-period position, plan-specific TER, latest AUM, and the limitations of the short performance record need accountable answers.
Decision rule
Do not move beyond research until the material gaps are resolved and a personalized fit review has not produced a stop condition.
Current result: pause. Research has created better questions, but it has not produced permission to act.
Five-stage handoff
Every stage produces a record
Freeze the research record
Save the exact strategy, plan, option, documents, values, dates, source locators, conflicts, and unresolved fields used in the review.
Output
Versioned evidence packet
Write the decision brief
State the intended role, verified facts, interpretation, open evidence, investor constraints, and explicit pause or stop conditions.
Output
One-page decision memo
Route each question
Send product questions to the AMC, personalized fit to a registered adviser, commercial terms to the chosen channel, and tax questions to a tax professional.
Output
Accountable answer owners
Record answers and proof
Capture who answered, on what date, what source supports the answer, and whether it resolves or changes the original research gap.
Output
Updated decision record
Run the final gate
Recheck current terms and intermediary identity. Continue only if material gaps are closed and no suitability, liquidity, cost, or risk stop remains.
Output
Continue, pause, or close
Question routing
Send each question to the party accountable for the answer
A product source, adviser, distributor, and tax professional solve different problems. Their answers should not be blended into one vague statement that the investment is suitable.
AMC or SIF service desk
Product facts- Ask
- Which current document confirms the notice period, plan-specific TER, fund manager, portfolio date, and applicable transaction terms?
- Keep as proof
- An exact official document, field locator, effective date, and written response where needed.
The AMC can clarify its product. That is not a personal suitability conclusion.
SEBI-registered Investment Adviser
Personalized fit- Ask
- Does this strategy have a justified role after considering goals, existing exposures, risk capacity, liquidity needs, horizon, and concentration?
- Keep as proof
- Registration status, scope of engagement, risk profile, suitability rationale, fees, and conflict disclosures.
Public research cannot perform an individual investor's risk profiling or recommendation.
Eligible distributor or official channel
Route and commercial terms- Ask
- Which plan and option will be used, what commission or fee applies, what documents are signed, and who services the transaction?
- Keep as proof
- Channel identity, plan and option, written cost disclosure, application trail, and transaction confirmation.
Distribution and execution economics should be visible before the investor acts.
Tax professional
Investor-specific tax- Ask
- How do the strategy's current classification, plan, transaction type, holding period, and the investor's facts affect tax treatment?
- Keep as proof
- Current law, scheme classification, investor facts, assumptions, and a dated written conclusion where material.
A scheme document or educational article cannot settle an individual's tax outcome.
Conversation ledger
Replace reassuring answers with reviewable answers
Question
Weak answer
Reviewable answer
What role does this SIF play?
Weak answer
It looks promising and has a strong AMC brand.
Reviewable answer
A named portfolio role, the exposure it complements or replaces, and the conditions under which that role is no longer needed.
What can make the strategy lose money?
Weak answer
It has long and short positions, so risk should be controlled.
Reviewable answer
A mechanics-based explanation covering market direction, selection, derivatives, allocation, liquidity, costs, concentration, and manager decisions.
When can capital be accessed?
Weak answer
NAV is published daily, so money should be available daily.
Reviewable answer
The exact redemption frequency, notice period, applicable NAV rule, exit load, settlement timeline, and any interval or liquidity provisions.
Why this route and plan?
Weak answer
This is the link the intermediary sent.
Reviewable answer
A written comparison of plan, option, service model, adviser fee or distributor commission, conflicts, and the responsible servicing entity.
Decision states
The final gate has three legitimate outcomes
Continue to action discussion
Core evidence is current, personalized fit has not failed, route and costs are understood, and the final recheck produces no material change.
Confirm the exact transaction instructions and retain the records.
Pause
A material answer is missing, stale, conflicting, verbal only, or attached to the wrong strategy, plan, option, date, or investor assumption.
Keep the product out of the action list until the gap is resolved.
Close the case
The investor does not understand the strategy, liquidity is unsuitable, concentration is excessive, risk exceeds capacity, or the capital is not genuinely surplus.
Document the reason. Better recent returns do not cancel a fit failure.
Final recheck
Research can become stale before action
Reopen the current official sources on the decision date. Confirm that nothing material changed after the research memo was prepared.
A previous pass does not survive a new addendum, changed Risk-band, changed manager, revised cost, different plan, or changed liquidity term.
Check 1
Identity
Exact SIF, strategy, code, plan, option, and official channel
Check 2
Freshness
Latest NAV context, Risk-band, addenda, TER, manager, portfolio, and dealing terms
Check 3
Economics
Adviser fee or distributor commission, plan cost, exit load, and other stated charges
Check 4
Fit
Role, horizon, liquidity buffer, loss capacity, concentration, and existing portfolio overlap
Check 5
Authority
Registration or channel status, official contact details, and grievance route
Check 6
Records
Application, disclosures, payment trail, confirmations, account statement, and nomination details
Closing principle
The workflow protects the decision, not the product
The purpose of the memo is not to create momentum toward investing. It is to preserve the evidence, expose conflicts, assign unanswered questions, and make it easy to stop when the case does not hold together.
Knowledge map
Terms to understand first
Decision brief
A one-page record of the intended portfolio role, verified facts, research interpretation, investor constraints, unresolved evidence, answer owners, and continue, pause, or stop conditions.
Research-to-advice boundary
Public education can explain products and evidence. Personalized advice requires the investor's goals, finances, risk profile, liquidity needs, horizon, existing portfolio, and an appropriately registered professional relationship.
Answer owner
The party accountable for a question: the AMC for official product facts, a SEBI-registered Investment Adviser for personalized fit, the chosen channel for route and commercial terms, or a tax professional for investor-specific tax.
Reviewable answer
An answer linked to the responder's identity, role, source, date, assumptions, and consequence for the decision. Reassurance without this trail does not close a research gap.
Final recheck
A fresh review of identity, addenda, Risk-band, manager, TER, portfolio, liquidity, plan, route, and disclosures immediately before any action discussion or instruction.
Close decision
A documented decision to remove the product from consideration because suitability failed or a material case cannot be resolved. It is different from a temporary research pause.
Section 1
Finish research with a memo, not a favourite
A shortlist can create attachment to a product before the unresolved facts are answered. Convert the leading candidate into a decision brief that gives equal space to verified evidence, interpretation, missing information, investor constraints, conflicts, and reasons to stop. The memo exists to test the case, not promote it.
Section 2
Keep public research and personal advice separate
elitefunds can organize public documents, compare observable data, explain strategy mechanics, and preserve evidence gaps. It does not know an investor's complete finances, goals, dependants, liabilities, tax position, portfolio, risk capacity, or behaviour. A product that is well documented can still be personally unsuitable.
Section 3
Route questions instead of collecting opinions
Ask the AMC to prove product terms, a SEBI-registered Investment Adviser to evaluate personalized fit, the selected distributor or official channel to disclose route and commercial terms, and a tax professional to evaluate investor-specific tax. Record where one party's role ends so that an answer is not trusted beyond its scope.
Section 4
Ask for proof that changes the decision
A useful answer identifies the exact document or professional rationale, its date, assumptions, and consequence for the open question. If a response cannot resolve the original evidence gap or explain why the investor's circumstances fit the strategy, it belongs in the notes but does not convert the gate to pass.
Section 5
Make costs and conflicts visible before action
Record whether the interaction is fee-based advice, distribution, referral, execution, or an official AMC route. Confirm the exact plan and option, adviser fee or distributor commission, service scope, exit load, stated charges, and who remains responsible for servicing. A product comparison is incomplete when its commercial path is hidden.
Section 6
Repeat the critical checks on the decision date
Research can become stale. Reopen the current ISID and addenda, Risk-band, manager, plan-specific TER, portfolio, NAV context, dealing terms, and official channel details. Record what changed since the memo date and reassess any gate affected by the change.
Section 7
Preserve the post-action record
If the investor ultimately acts through an appropriate channel, retain the application, plan and option, disclosures, payment trail, transaction confirmation, statement, service contacts, nomination details, and review calendar. These records support monitoring, correction, and grievance escalation without relying on memory or informal messages.
Section 8
Let pause and closure protect the investor
A pause is appropriate when a material answer is missing or stale. Closure is appropriate when fit fails or the case remains unconvincing after review. Neither outcome is wasted effort: both prevent the research process from manufacturing momentum toward a product.
Mistakes to avoid
Treating completion of research as an obligation to invest.
Asking one person to answer product facts, personal suitability, commercial terms, and tax without separating their roles and incentives.
Accepting a verbal assurance when the original gap required a dated official source or written rationale.
Using an old decision brief after a new addendum, manager change, Risk-band change, cost update, or liquidity revision.
Allowing a strong recent return to override liquidity, concentration, complexity, or loss-capacity concerns.
Failing to verify the registration or status of the person or channel involved.
Leaving plan, option, adviser fee, distributor commission, servicing entity, or conflicts implicit until after action.
Sharing passwords, one-time codes, or account control with another person as part of an assisted process.
Two-minute recap
What should stay with you
- 1
The final research output is a dated decision brief, not a recommendation.
- 2
Product facts, personalized fit, route economics, and tax belong to different accountable parties.
- 3
A reviewable answer includes identity, role, proof, date, assumptions, and a decision consequence.
- 4
Recheck current sources and intermediary status immediately before any action.
- 5
Continue, pause, and close are equally legitimate workflow results.
Practical checklist
Before you rely on this topic
Freeze the exact SIF, strategy, code, plan, option, values, source locators, and review dates.
Write the intended portfolio role and what existing exposure the strategy would complement or replace.
Separate verified facts, interpretation, conflicts, open evidence, and investor constraints.
Assign every unresolved question to the AMC, registered adviser, selected channel, or tax professional as appropriate.
Verify intermediary or channel identity and status through official sources.
Record fees, commissions, plan economics, service scope, conflicts, and grievance route before action.
Require reviewable answers with dates, proof, assumptions, and consequences for the decision.
Reopen current addenda, Risk-band, TER, manager, portfolio, NAV context, and liquidity terms on the decision date.
Do not share passwords, one-time codes, or uncontrolled account access with another person.
Classify the case as continue to action discussion, pause, or close and record the reason.
Source trail
Where to verify next
SEBI guide to Investment Advisers
Understand the role of a SEBI-registered Investment Adviser, personalized risk profiling and suitability, fees, conflicts, and grievance channels.
SEBI intermediary registration support
Use SEBI's investor-support route to check the registration status of a market intermediary and locate official support and complaint information.
SEBI investing dos and don'ts
Review official cautions on understanding documents and charges, dealing with registered intermediaries, retaining records, avoiding borrowed investment money, and protecting account credentials.
AMFI SIF investor corner
Return to official SIF factsheets, portfolio disclosures, Risk-band information, annual reports, NAV resources, and official transaction channels.
SIF due-diligence checklist
Complete the seven product and evidence gates before preparing the decision brief and routing questions to external parties.
elitefunds disclaimer
Review the boundary between public educational research, official source precedence, personalized advice, and transaction responsibility.
Continue this pathway
Related SIF guides
Risk / 13 min read
How to read SIF risk and liquidity
A visual investor guide to the five-level Risk-band, strategy risks, redemption windows, notice periods, exit costs, and the difference between daily NAV and available cash.
Risk / 14 min read
How to read SIF costs and tax notes
A visual guide to TER, Direct and Regular plans, transaction costs, exit load, switches, and the facts needed before calculating personal tax.
Start here / 12 min read
What is a Specialized Investment Fund?
A visual, beginner-friendly introduction to India's Specialized Investment Fund framework, the ₹10 lakh threshold, strategy flexibility, liquidity, risk, and source documents.